Stockreport

TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs

Tyme Technologies, Inc.  (TYME) 
Last tyme technologies, inc. earnings: 2/5 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: tymeinc.com/investors
PDF New oral approach aimed at disrupting cancer metabolismSM-88 is an investigational Cancer Metabolism-Based Therapy (CMBTsTM) that has demonstrated responses across 15 di [Read more]